Aarti Drugs Limited Cash Flow Conversion Efficiency
Aarti Drugs Limited cash flow conversion efficiency. Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) has a cash flow conversion efficiency ratio of 0.104x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs1.52 Billion ≈ $16.48 Million USD) by net assets (Rs14.69 Billion ≈ $158.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aarti Drugs Limited (2007–2026)
Cash flow conversion efficiency of Aarti Drugs Limited from 2007 to 2026. This chart illustrates how Aarti Drugs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Aarti Drugs Limited for real-time trading data and today's change.
Aarti Drugs Limited Cash Flow Conversion Ratio Explained
Aarti Drugs Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aarti Drugs Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aarti Drugs Limited ranked by their cash flow conversion efficiency. Also see AARTIDRUGS market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jee Technology Co. Ltd. A
SHG:688162
|
N/A |
|
CapitaLand Malaysia Mall Trust
KLSE:5180
|
0.021x |
|
Hailir Pesticides and Chemicals Group Co Ltd
SHG:603639
|
0.047x |
|
Hainan Shuangcheng Pharmaceut
SHE:002693
|
0.078x |
|
SKS Technologies Group Ltd
AU:SKS
|
0.652x |
|
Shanghai Kindly Entrp Dvlp Grp
SHG:603987
|
0.040x |
|
Kedge Construction Co Ltd
TW:2546
|
-0.134x |
|
Brisa Bridgestone Sabanci Lastik Sanayi ve Ticaret AS
IS:BRISA
|
0.058x |
Annual Cash Flow Conversion Efficiency for Aarti Drugs Limited (2007–2026)
The table below shows the annual cash flow conversion efficiency of Aarti Drugs Limited from 2007 to 2026. Review free cash flow generation of Aarti Drugs Limited to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs15.49 Billion ≈ $167.54 Million |
Rs2.22 Billion ≈ $24.05 Million |
0.144x | -19.62% |
| 2025-03-31 | Rs13.69 Billion ≈ $148.09 Million |
Rs2.45 Billion ≈ $26.45 Million |
0.179x | -36.21% |
| 2024-03-31 | Rs12.82 Billion ≈ $138.64 Million |
Rs3.59 Billion ≈ $38.82 Million |
0.280x | +148.83% |
| 2023-03-31 | Rs11.93 Billion ≈ $128.98 Million |
Rs1.34 Billion ≈ $14.51 Million |
0.113x | +67.45% |
| 2022-03-31 | Rs10.36 Billion ≈ $112.07 Million |
Rs696.36 Million ≈ $7.53 Million |
0.067x | -60.36% |
| 2021-03-31 | Rs9.13 Billion ≈ $98.78 Million |
Rs1.55 Billion ≈ $16.75 Million |
0.170x | -55.88% |
| 2020-03-31 | Rs6.52 Billion ≈ $70.56 Million |
Rs2.51 Billion ≈ $27.12 Million |
0.384x | +45.95% |
| 2019-03-31 | Rs5.43 Billion ≈ $58.77 Million |
Rs1.43 Billion ≈ $15.47 Million |
0.263x | +71.88% |
| 2018-03-31 | Rs4.55 Billion ≈ $49.25 Million |
Rs697.66 Million ≈ $7.54 Million |
0.153x | -63.96% |
| 2017-03-31 | Rs4.11 Billion ≈ $44.42 Million |
Rs1.75 Billion ≈ $18.88 Million |
0.425x | +13.96% |
| 2016-03-31 | Rs3.57 Billion ≈ $38.65 Million |
Rs1.33 Billion ≈ $14.42 Million |
0.373x | +9.88% |
| 2015-03-31 | Rs3.08 Billion ≈ $33.33 Million |
Rs1.05 Billion ≈ $11.31 Million |
0.339x | -10.76% |
| 2014-03-31 | Rs2.51 Billion ≈ $27.13 Million |
Rs954.26 Million ≈ $10.32 Million |
0.380x | +6.26% |
| 2013-03-31 | Rs2.08 Billion ≈ $22.45 Million |
Rs743.10 Million ≈ $8.04 Million |
0.358x | +72.40% |
| 2012-03-31 | Rs1.76 Billion ≈ $19.09 Million |
Rs366.41 Million ≈ $3.96 Million |
0.208x | +64.76% |
| 2011-03-31 | Rs1.63 Billion ≈ $17.65 Million |
Rs205.60 Million ≈ $2.22 Million |
0.126x | -68.79% |
| 2010-03-31 | Rs1.46 Billion ≈ $15.84 Million |
Rs591.20 Million ≈ $6.39 Million |
0.404x | -18.58% |
| 2009-03-31 | Rs1.23 Billion ≈ $13.35 Million |
Rs612.10 Million ≈ $6.62 Million |
0.496x | +94.81% |
| 2008-03-31 | Rs1.12 Billion ≈ $12.06 Million |
Rs283.87 Million ≈ $3.07 Million |
0.255x | -12.94% |
| 2007-03-31 | Rs1.00 Billion ≈ $10.83 Million |
Rs292.69 Million ≈ $3.17 Million |
0.292x | -- |
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more